Modulus Biotech specializes in biopharmaceutical business development. We link drug discovery scientists with pharmaceutical companies. Our expertise is in identifying, structuring, negotiating, and managing co-development partnerships, license agreements, and other commercial transactions in the pharmaceutical and biotechnology sectors. We provide exclusive scientific representation to distinguished scientists whose patented and near-patented molecules sit at the cutting edge of bioscience, structuring the pharma co-development deals that advance those discoveries from the laboratory into clinical development. Our practice focuses on rare diseases and oncology — the therapeutic areas where breakthrough science means the most.
Between 2025 and 2030, a wave of major patent expirations is pulling billions in annual revenue out of large pharma's established portfolios — a financial cliff driving urgent demand for new pipeline assets. Modulus represents the scientists whose molecules can fill that gap.
Our incentives align with the discovery, the inventor, and the advancement of meaningful therapeutic outcomes — particularly in rare diseases and oncology, where the successful translation of these molecules into approved therapies depends on disciplined representation.
We work directly and exclusively with scientists whose molecules sit at the cutting edge of bioscience — protecting their interests, managing the business side, and freeing them to stay focused on the research.
We identify, negotiate, and manage co-development partnerships, license agreements, and commercial transactions on your behalf.
Special emphasis on the therapeutic areas where breakthrough science means the most: rare and orphan diseases, and oncology — the indications where conventional development pipelines have historically fallen short.
We identify and approach the specific pharmaceutical companies whose pipelines, therapeutic focus, and development stage make them real candidates — not blast lists.
Term sheets, milestone payments, royalty structures, co-development economics — we negotiate the agreement the science deserves, not the first one offered.
Every conversation, every disclosure, every term sheet — held in strictest confidence. We are the scientist's voice in every room they're not in, and the firewall protecting their work in every room they are.
As Chief Executive Officer at Modulus Biotech, I lead our mission to bring transformative antiviral and cancer drugs to market.
If you are a distinguished scientist and have a proven record of successfully participating in bringing new drugs to market, we would like to hear from you to discuss how you can bypass traditional mechanisms for drug development. If you are interested in hearing how we can assist you, please provide your information in the inquiry section. All communications are held in strictest confidence.
Over 10 years experience in infectious disease and general acute care hospitals at C-suite level.
Got a question, an idea, or just want to say hi? Drop Anthony a line. He reads everything, and replies personally.
We represent distinguished drug discovery scientists with proven records of discovering patented or near-patented molecules at the cutting edge of bioscience — with special emphasis on rare diseases and oncology. Submit the form below to begin a conversation about exclusive representation.
All submissions are reviewed personally and held in strict confidence. Please share what you're comfortable sharing publicly — anything sensitive can be expanded under an NDA before further discussion.